Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 8/20 | 0.53 |
| ▸ | POLB | P06746 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | TP53 | P04637 | 14/20 | 0.52 |
| ▸ | MAPT | P10636 | 6/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5930436 | 0.92 | LMNA (0.52) | LMNAPOLBKDM4ESMN1; SMN2HTT | |
| SCHEMBL4906013 | 0.91 | LMNA (0.59) | LMNAPOLBKDM4ESMN1; SMN2HTT | |
| SCHEMBL4904167 | 0.91 | MAPT (0.55) | LMNAPOLBTP53MAPT | |
| SCHEMBL4895726 | 0.90 | SHMT2 (0.47) | LMNAPOLBKDM4ESMN1; SMN2HTT | |
| SCHEMBL4904002 | 0.89 | MAPT (0.59) | LMNATP53MAPT | |
| SCHEMBL4906047 | 0.87 | LMNA (0.52) | LMNAPOLBKDM4ESMN1; SMN2HTT | |
| SCHEMBL4906542 | 0.86 | LMNA (0.58) | LMNAPOLBKDM4ESMN1; SMN2HTT | |
| SCHEMBL4895694 | 0.85 | LMNA (0.65) | LMNAPOLBKDM4ESMN1; SMN2HTT | |
| SCHEMBL4904971 | 0.85 | MAPT (0.61) | LMNAPOLBKDM4ESMN1; SMN2HTT | |
| SCHEMBL4906731 | 0.85 | MAPT (0.63) | LMNAKDM4ESMN1; SMN2HTTTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080090829-A1 | SUBSTITUTED HETEROARYL- AND PHENYLSULFAMOYL COMPOUNDS | PFIZER INC. | 2008-04-17 | — | — | US | disclosed |
| US-20080090829-A1 | SUBSTITUTED HETEROARYL- AND PHENYLSULFAMOYL COMPOUNDS | PFIZER INC. | 2008-04-17 | — | — | US | disclosed |
| US-20080090829-A1 | SUBSTITUTED HETEROARYL- AND PHENYLSULFAMOYL COMPOUNDS | PFIZER INC. | 2008-04-17 | — | — | US | disclosed |
| US-20050288340-A1 | Substituted heteroaryl- and phenylsulfamoyl compounds | PFIZER INC | 2005-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050288340-A1 | Substituted heteroaryl- and phenylsulfamoyl compounds | PPARA, PPARG, PPARD | LMNA 319/4885POLB 1807/4885KDM4E 3834/4885 |
| US-20080090829-A1 | SUBSTITUTED HETEROARYL- AND PHENYLSULFAMOYL COMPOUNDS | PPARA, PPARG, PPARD | LMNA 319/4885POLB 1807/4885KDM4E 3834/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.